ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / INSP
XRAY (32) LMAT (67) KMTS (50) UFPT (74) ⌘ Pro Terminal →

Inspire Medical Systems Inc. (INSP) — RQD Stock Rating Cockpit

$67.21 -1.31% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $66.92

Inspire Medical Systems Inc. (INSP) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $1.97B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INSP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INSP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Inspire Medical Systems Inc. (NYSE: INSP) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $67.21 (-1.31% 1D, market cap $1.97B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, INSP ranks #117 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INSP compare to XRAY and LMAT in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), INSP carries a Roarable C (65/100 RQD), trailing P/E of 14.2x, gross margin of 85.4%, and ROIC of 6.0%. By comparison, XRAY (DENTSPLY SIRONA Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -11.0%, cap $1.90B) and LMAT (LeMaitre Vascular Inc.) posts a C+ grade (67/100 RQD, P/E 33.8x, ROIC 14.7%, cap $1.85B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INSP?
▼

Per INSP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001609550), Inspire Medical Systems Inc. generated $912.0M in revenue (+13.6% YoY), $145.4M in net income, and $78.5M in free cash flow against $907.3M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $66.92 (-0.43%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 8.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY • 55.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510065
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B+
Cash (8)Whales (10)SEC (18)Macro (13)CEO (16)
Each axis scored 0–20
12M PRICE TARGET CONE+3.2% Base Target
$154 Bull$69 Base$54 Bear
📬 FREE INSP RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INSP)Realized 20D OHLCV Swing Band: ±7.4%
Deterministic 5-Pillar Attribution (65/100 Composite)
🔍 WHY INSP SCORES 65/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (28% of score)

Altman Z-Score 11.40 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+16/20 pts (25% of score)

SEC Form 4 / 13F Thermometer: 80% Net Buy • Cannibal Buyback (-2.36% YoY Shares)

▼ #1 Drag / Risk Factor: Cash Engine Quality8/20 pts (-12 pt drag)

Capital intensity & 5.6% operating margin leave 12 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
73
Grade B$68.86+3.6% Next Q
Q2 (-2Q)
70
Grade B$71.34-0.1% Next Q
Q3 (-1Q)
68
Grade B-$71.30-5.7% Next Q
Current
65
Grade C$67.21+1.3% Hist 90D α
Trajectory: B (73) → C (65)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the INSP Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 65/100 (C) score, INSP faces multiple-compression risk if 14.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 82.9% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($68.90) or 200D SMA ($58.33) invalidates the momentum regime and cuts Target Base ($69.33) toward Bear Floor ($54.08).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INSP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “INSP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 65%NO 35%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
46.130 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
11.40>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE26% OF RANGE
L: $39$67.21H: $147
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: CRQD 26 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B+RQD 31 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on INSP

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

6.0% ROIC with 85.4% gross margin and 3.81% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (90)

Altman-Z 11.40 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (65)

26/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like INSP
  • ✓Company leadership has skin in the game with net positive insider conviction.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (INSP Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
INSP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +22.56%🛡️ HOLDING TREND SUPPORT
2026-11-03O $71.18H $71.18L $67.21C $67.21VOL 796.4K
RES: $91.39SUP: $65.55SMA50: $68.90SMA200: $58.33
$85.96$73.21$60.46$47.70$34.95RES $91.39SUP $65.55$67.212026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INSP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INSP Butterfly Map → + Track INSP →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
6.0%/yr Implied 5Y Growth

vs. +13.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on INSP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INSP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INSP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INSP)

Health Care Rank #117 of 1015 ⚔️ XRAY vs INSP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INSP vs. XRAY, LMAT, KMTS, UFPT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Inspire Medical Systems Inc. (INSP) ranks #117 by composite RQD confidence (65/100, grade C) and #256 by equity capitalization ($1.97B). Within this direct 5-issuer industry benchmark cohort, INSP leads on earnings valuation at 14.2x trailing P/E, while LMAT leads on capital efficiency and profitability with 14.7% ROIC and 71.5% gross margin. UFPT currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with INSP at 65/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
INSP ACTIVE
Inspire Medical Systems Inc.
C 65/100 14.2x 85.4% 6.0% -1.31% $1.97B Benchmark Subject
XRAY
DENTSPLY SIRONA Inc.
E 32/100 — 50.0% -11.0% +3.88% $1.90B /xray-vs-insp →
LMAT
LeMaitre Vascular Inc.
C+ 67/100 33.8x 71.5% 14.7% +0.40% $1.85B /lmat-vs-insp →
KMTS
Kestra Medical Technologies Ltd.
D 50/100 — 51.4% -35.0% +0.40% $1.77B /kmts-vs-insp →
UFPT
UFP Technologies Inc.
B 74/100 33.3x 28.3% 13.9% -0.19% $2.20B /ufpt-vs-insp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001609550 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Inspire Medical Systems Inc. (INSP) reported GAAP revenue of $912.0M (+13.6% vs. FY2024 revenue of $802.8M , and +46.0% cumulative change since FY2023) , GAAP net income of $145.4M, operating cash flow of $117.0M, and free cash flow of $78.5M (-13.9% YoY). On the balance sheet, INSP closed FY2025 with $907.3M in total assets against $0 in total debt (Altman Z-Score: 11.40, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $912.0M $145.4M $117.0M $78.5M $907.3M —
FY2024 (FY) 2024-12-31 $802.8M $53.5M $130.2M $91.1M $808.4M —
FY2023 (FY) 2023-12-31 $624.8M -$21.2M $24.7M $24.7M — —

3. INSP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INSP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Inspire Medical Systems Inc. (NYSE: INSP) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $67.21 (-1.31% 1D, market cap $1.97B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, INSP ranks #117 in composite RQD confidence.

How does INSP compare to XRAY and LMAT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), INSP carries a Roarable C (65/100 RQD), trailing P/E of 14.2x, gross margin of 85.4%, and ROIC of 6.0%. By comparison, XRAY (DENTSPLY SIRONA Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -11.0%, cap $1.90B) and LMAT (LeMaitre Vascular Inc.) posts a C+ grade (67/100 RQD, P/E 33.8x, ROIC 14.7%, cap $1.85B). Among the 5-stock peer group, INSP leads on earnings multiple (14.2x) while LMAT leads on capital efficiency (14.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INSP?

Per INSP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001609550), Inspire Medical Systems Inc. generated $912.0M in revenue (+13.6% YoY), $145.4M in net income, and $78.5M in free cash flow against $907.3M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INSP trading relative to its 50-day, 200-day, and 52-week technical levels?

INSP last traded at $67.21 (-1.31% on volume of 1,075,962 shares), positioning the stock -2.45% below its 50-day simple moving average ($68.90) and +15.22% above its 200-day simple moving average ($58.33). Across its 52-week range of $38.91 to $147.03, INSP sits at the 26.2% percentile with a 14-day RSI of 46.1 (NEUTRAL RANGE) and an implied next-earnings move of ±7.4% ($62.24 to $72.18).

Direct Sub-Reports: INSP RQD Cockpit INSP 12M Forecast INSP Earnings & Move INSP Dividends & DRIP INSP Insiders & 13F INSP Whale Options INSP Profit Sankey INSP News & Why
ROARABLE RATING BRIEF • RQD 65/100 (C) ✓ SEC XBRL & RQD VERIFIED

INSP — Inspire Medical Systems Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Inspire Medical Systems Inc. (INSP) earns a live Roarable RQD composite score of 65/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $67.21 (-1.31% 1D, market capitalization $1.97B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of 6.0%, gross margin of 85.4%, operating margin of 5.6%, and free cash flow yield of 3.81%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (13/20) + Forensic Balance Sheet (18/20): Incorporates a 1.00x equity beta, Altman Z-Score of 11.40, Piotroski F-Score of 7/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Inspire Medical Systems Inc. Is a NYSE-listed issuer in the Health Care sector, Medical/Dental Instruments industry. It operates as a publicly traded medical instruments company.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Inspire Medical Systems Inc. (INSP) reported $912.0M in annual revenue (up from $802.8M in FY2024, +13.6% YoY) and $145.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($624.8M revenue, -$21.2M net income) through FY2025, INSP scaled operating cash flow to $117.0M and free cash flow to $78.5M, backed by $907.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C • RQD 65/100): Company leadership has skin in the game with net positive insider conviction. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $38.91 – $147.03 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 14.2x trailing P/E and 23.3x EV/EBITDA against 5.6% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

—: upstream suppliers, downstream customers, and sector correlation figures. Investors seeking second-order ripple analysis would need supplier and customer disclosures not present in this dataset.

  • Key Question #1: Can INSP sustain or expand its 5.6% operating margin and 6.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $912.0M and free cash flow of $78.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is INSP's 11.9x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

INSP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Inspire Medical Systems Inc. (INSP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to INSP Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INSP Bull vs. Bear Conversation Board — What's Your Call at $67.21?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INSP 🐻 33% BEARISH CONVICTION
1. Pick Your Side on INSP:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $86.49 (+27.0%)
📌 Pinned Debate

Strong forensic balance sheet (Altman Z 11.4, Piotroski F 7/9, Debt/Equity 0.5) and revenue growth from $624.8M to $912.0M support the

Strong forensic balance sheet (Altman Z 11.4, Piotroski F 7/9, Debt/Equity 0.5) and revenue growth from $624.8M to $912.0M support the upper-neutral rating.. When you look under the hood at INSP, Fundamental Cash Engine is 8/20 with 85.4% gross margins and 6.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (10/20) has been quietly accumulating below $147.03. My 12M target is $86.49.

ArenaChamp_24 🐂 BULL

@RedlineAuditor Fair point on 14.2x trailing P/E, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (85.4%) holds, EPS grows into the multiple faster than bears think.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $58.57 (-14.0%)
Spot @ $68.10

ROIC of 6%, a 3.81% FCF yield, and declining FY 2025 FCF and cash ($78.5M and $104.8M, down from $91.1M and $150.2M) weaken the cash-ge

Careful chasing INSP at $68.10. ROIC of 6%, a 3.81% FCF yield, and declining FY 2025 FCF and cash ($78.5M and $104.8M, down from $91.1M and $150.2M) weaken the cash-generation case.. Gross margin is 85.4%, but operating margin is 5.6%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $58.57 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%